Polypeptide therapy for epilepsy

Abstract

Goal. Investigate the role of cortexin in stopping and achieving remission of seizures in epilepsy.Material and methods. 47 patients with various forms of epilepsy were examined at the reception of a neurologist of the polyclinic department of the United City Hospital No. 7 during 2020–2021. To assess the psycho-emotional status, the Ziqmond scale was used. As a means of increasing stress resistance, cortexin was used. Statistical calculations of qualitative parameters were carried out using the Fisher criterion. The results are presented at the level of reliable significance p < 0.05.Results and discussion. Psychoemotional status, determined by the Ziqmond scale before treatment with cortexin, was rated low in all patients (6.91 ± 0.13; m = 4, M = 11), and in female patients statistically significantly lower (8.05 ± 0.32; m = 6, M = 13) than in male (8.83 ± 0.21; m = 5, M = 12), (p = 0.046). During the study period (1 year), in 39 patients (35 cases from the group taking cortexin and 4 cases from the placebo group), seizures did not recur. The study proved a fairly high (72.9%) effectiveness of cortexin in improving the mental and emotional states of patients with epilepsy. didn't repeat themselves.Conclusions. The inclusion of cortexin in the interictal period in the treatment regimen allows you to achieve a thymoleptic effect and prolong the remission of epileptic seizures.